Cassava Sciences/SAVA

$22.11

2.55%
-
1D1W1MYTD1YMAX

About Cassava Sciences

Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.

Ticker

SAVA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Remi Barbier

Employees

29

Headquarters

Austin, United States

Cassava Sciences Metrics

BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$1.17
EPS
-0.48
Beta
-
Dividend rate
$1.1B
-0.48471
$32.10
$12.32
832K
1.738
-25.63%
-33.9%
-33.88%
12.661
14.066
42.64%

What the Analysts think about Cassava Sciences

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
350.02% upside
High $124.00
Low $75.00
$22.11
Current price
$99.50
Average price target

Cassava Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
$25M
-219.62%
Profit margin
0%
NaN%

Cassava Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 226.09%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.63
-$0.61
-$0.50
$0.58
-
Expected
-$0.59
-$0.78
-$0.52
-$0.46
-$0.45
Surprise
6.78%
-21.29%
-3.85%
-226.09%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cassava Sciences stock?

Cassava Sciences (SAVA) has a market cap of $1.1B as of May 18, 2024.

What is the P/E ratio for Cassava Sciences stock?

The price to earnings (P/E) ratio for Cassava Sciences (SAVA) stock is 0 as of May 18, 2024.

Does Cassava Sciences stock pay dividends?

No, Cassava Sciences (SAVA) stock does not pay dividends to its shareholders as of May 18, 2024.

When is the next Cassava Sciences dividend payment date?

Cassava Sciences (SAVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Cassava Sciences?

Cassava Sciences (SAVA) has a beta rating of -0.48. This means that it has an inverse relation to market volatility.

What is the Cassava Sciences stock price target?

The target price for Cassava Sciences (SAVA) stock is $99.5, which is 330.36% above the current price of $23.12. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cassava Sciences stock

Buy or sell Cassava Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing